Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- BNTX
- Price
- 102.34
- Stock movement up
- +5.82 (6.03%)
- Company name
- BioNTech SE
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 24.53B
- Ent value
- 18.20B
- Price/Sales
- 8.07
- Price/Book
- 1.28
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 17.62%
- 3 year return
- -15.42%
- 5 year return
- 17.89%
- 10 year return
- -
Last updated: 2025-04-14
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
BNTX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | 16.12 |
| Price to FCF | 25.29 |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 8.07 |
| Price to Book | 1.28 |
| EV to Sales | 5.99 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 239.74M |
| EPS (TTM) | -1.91 |
| FCF per share (TTM) | 3.97 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 3.04B |
| Gross profit (TTM) | 2.56B |
| Operating income (TTM) | -936.70M |
| Net income (TTM) | -466.90M |
| EPS (TTM) | -1.91 |
| EPS (1y forward) | -3.34 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 84.31% |
| Operating margin (TTM) | -30.81% |
| Profit margin (TTM) | -15.36% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 9.62B |
| Net receivables | 1.20B |
| Total current assets | 18.49B |
| Goodwill | 374.00M |
| Intangible assets | 873.90M |
| Property, plant and equipment | 1.16B |
| Total assets | 22.40B |
| Accounts payable | 762.60M |
| Short/Current long term debt | 243.70M |
| Total current liabilities | 2.52B |
| Total liabilities | 3.29B |
| Shareholder's equity | 19.11B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 1.52B |
| Capital expenditures (TTM) | 551.93M |
| Free cash flow (TTM) | 969.97M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -2.44% |
| Return on Assets | -2.08% |
| Return on Invested Capital | -2.41% |
| Cash Return on Invested Capital | 5.01% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 99.17 |
| Daily high | 103.59 |
| Daily low | 98.09 |
| Daily Volume | 1.79M |
| All-time high | 447.23 |
| 1y analyst estimate | 137.65 |
| Beta | 0.26 |
| EPS (TTM) | -1.91 |
| Dividend per share | - |
| Ex-div date | 2 Jun 2022 |
| Next earnings date | 16 May 2025 |
Downside potential
Loading...
Downside potential data
| BNTX | S&P500 | |
| Current price drop from All-time high | -77.12% | -12.04% |
| Highest price drop | -82.48% | -56.47% |
| Date of highest drop | 5 Aug 2024 | 9 Mar 2009 |
| Avg drop from high | -52.19% | -11.07% |
| Avg time to new high | 24 days | 12 days |
| Max time to new high | 925 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
24.53B
Marketcap category
Large-cap
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac
Employees
6133
Website
Investor relations
-
SEC filings
CEO
Ugur Sahin
Country
USA
City
Mainz
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page